Comparing Eloxx Pharmaceuticals (NASDAQ:ELOX) & Alpha Cognition (OTC:ACOGF)

Alpha Cognition (OTC:ACOGF) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Institutional & Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 31.5% of Alpha Cognition shares are held by company insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Alpha Cognition and Eloxx Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	N/A	N/A	-$13.77 million	C($0.12)	N/A
Eloxx Pharmaceuticals	N/A	N/A	-$36.06 million	($9.07)	0.00

Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alpha Cognition and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-522.43%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings for Alpha Cognition and Eloxx Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	2	0	3.00
Eloxx Pharmaceuticals	0	0	0	0	0.00

Given Alpha Cognition’s stronger consensus rating and higher possible upside, equities analysts clearly believe Alpha Cognition is more favorable than Eloxx Pharmaceuticals.

Volatility and Risk

Alpha Cognition has a beta of 2.8, meaning that its share price is 180% more volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1720.35, meaning that its share price is 172,135% less volatile than the S&P 500.

Summary

Alpha Cognition beats Eloxx Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

About Alpha Cognition

Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.